A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2463 participants.
Also called NCT04825743
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,463 participants
- Sponsor
- CeleCor Therapeutics
- Registry
-
NCT04825743
-
- Other papers using this trial's data
- The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Canada, Czechia, France, Hungary, Mexico, Netherlands, Romania
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04825743. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-24 (actual); primary completion 2026-05-13 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
- Acronym
- CELEBRATE
- Condition
- ST-elevation Myocardial Infarction (STEMI)
- Intervention (Drug)
- zalunfiban
- Intervention (Drug)
- Placebo
- Lead sponsor
- CeleCor Therapeutics
Record details
- Record id
cardio:ct-nct04825743- Content hash
c1b40e46d60959f3bf775273197e83e8aaed198eb7c73d36e428e4f087b7c2af